These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 17267077)

  • 21. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
    Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
    Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
    Giglio N; Micone P; Gentile A
    Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
    Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
    Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
    Paradiso P
    Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy.
    Fletcher MA; Schmoele-Thoma B; Vojicic J; Daigle D; Paradiso PR; Del Carmen Morales G
    Expert Rev Vaccines; 2024; 23(1):944-957. PubMed ID: 39279631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
    Bechini A; Boccalini S; Bonanni P
    Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
    Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
    Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunisation with a pneumococcal 7-valent conjugate vaccine.
    Dagan R
    Int J Clin Pract; 2002 May; 56(4):287-91. PubMed ID: 12074212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
    Paradiso PR
    Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
    Esposito S; Principi N
    Future Microbiol; 2019 Jul; 14():921-923. PubMed ID: 31373218
    [No Abstract]   [Full Text] [Related]  

  • 37. Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines.
    Ansaldi F; de Florentis D; Canepa P; Bandettini R; Diana MC; Martini M; Durando P; Icardi G
    Hum Vaccin; 2011; 7 Suppl():211-6. PubMed ID: 21546795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method.
    Rückinger S; van der Linden M; Reinert RR; von Kries R
    Vaccine; 2010 Jul; 28(31):5012-6. PubMed ID: 20546832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
    Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
    Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.